Gold prices fall as geopolitical tensions ease; U.S. CPI looms
HAIKOU, China - China Pharma Holdings Inc. (NYSE American: CPHI), a specialty pharmaceutical company facing significant challenges with its stock down 30% over the past year and trading between $0.13 and $0.41 in the past 52 weeks, has announced a 1-for-10 reverse stock split of its common stock, effective Tuesday, April 15, 2025. According to InvestingPro data, the company’s shares have experienced high price volatility, with 8 additional key insights available to subscribers. The company’s shares will continue trading on the NYSE American under the ticker symbol "CPHI" with the new CUSIP number 16941T 401 starting from the market open on the aforementioned date.
The reverse stock split was unanimously approved by the Board of Directors on October 22, 2024, and subsequently ratified by the stockholders at the Annual Meeting for the fiscal year ended December 31, 2023, which took place on December 22, 2024. The Board determined the final ratio of 1:10 on March 26, 2025. The decision comes as the company faces financial headwinds, with InvestingPro reporting negative EBITDA of $1.97M and a 35% year-over-year revenue decline to $4.53M in the last twelve months.
This corporate action will convert every 10 shares of China Pharma’s issued and outstanding common stock into one share. Fractional shares will not be issued; instead, shareholders will receive rounded up whole shares in the event of fractional entitlements. The reverse stock split is designed to affect all shareholders uniformly and will not change any shareholder’s percentage interest in the company’s outstanding common stock, except for minor adjustments due to the rounding of fractional shares.
China Pharma Holdings specializes in developing, manufacturing, and marketing pharmaceutical products aimed at treating diseases with high incidence and mortality rates in China, such as cardiovascular, CNS, infectious, and digestive diseases. The company operates a GMP-certified product line and has an extensive distribution network across China. However, InvestingPro analysis indicates concerning fundamentals, with a weak Financial Health Score of 1.21 and current ratio of 0.65, suggesting potential liquidity challenges.
The information provided in this article is based on a press release statement from China Pharma Holdings, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.